Madrigal Pharmaceuticals has hired a former Novartis executive to succeed its retiring founder as chief medical officer.

Madrigal Pharmaceuticals (MDGL) announced that Rebecca Taub, M.D., the company’s founder, Chief Medical Officer, and President of Research ...

April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report), with ...

Data from patients across 3 different randomized controlled trials showed improvements in both adiponectin and PRO-C3, primary end points in the trials.

At close: April 14 at 4:00:02 p.m. EDT ...

89bio, Inc. is a clinical-stage biotech focused on liver and cardio-metabolic diseases, with its lead drug candidate ...

Discover how Viking Therapeutics, Inc.'s VK2735 and VK2809 target obesity and NASH markets. Click for my updated look at VKTX ...

Madrigal said that all patients enrolled in MAESTRO-NASH - which include up to 2,000 in total - are continuing on therapy after the initial 52-week treatment period.

The Acquisition expands U.S. Energy's CCUS-ready infrastructure and reflects the Company's broader strategy to develop scalable, low-emission industrial gas operations while positioning itself as a ...